Skip to main content
. Author manuscript; available in PMC: 2015 Feb 15.
Published in final edited form as: Clin Cancer Res. 2013 Dec 9;20(4):890–903. doi: 10.1158/1078-0432.CCR-13-1982

Figure 2.

Figure 2

Immunohistochemical assessment of PTEN and p53 tumor suppressor loss in small cell carcinomas and their associated acinar carcinoma component. (A) Case 24 shows PTEN loss in both the small cell and associated acinar carcinoma, with retained endothelial/stromal staining for PTEN providing an internal positive control. Case 29 shows p53 accumulation in the small cell component only. (B) Immunohistochemistry for Rb, PTEN and p53 in Case 5 demonstrates loss of Rb and PTEN, with over-expression for p53. (C) Copy number by nanoString nCounter Cancer CNV Panel across 86 probed genes for Case 5. c-MYC amplification (5 copies), and hemizygous PTEN and RB1 loss are present. (D) Sanger sequencing chromatogram for TP53 from Case 5 shows a two base pair missense mutation (exon 7: c.695_696TC>AA) predicted to deleteriously affect the DNA binding domain.